Efectos cognitivos y conductuales secundarios al consumo de metanfetaminas.
Palabras clave:
MDMA, Metanfetaminas, Abuso de sustancias, Cognición, Cerebro adictoResumen
El éxtasis o 3,4-metilenedioxmetanfetamina (MDMA), es una droga simpaticomimética de metabolismo hepático, popular entre los jóvenes por sus efectos de euforia, extroversión, experiencias sensoriales aumentadas, desrealización moderada, empatía y facilitación de las relaciones interpersonales. El presente artículo revisa a profundidad el tema de los efectos cognitivos y conductuales agudos, subagudos y crónicos generados por el consumo de MDMA de acuerdo a literatura publicada entre 2000-2020. Se describen cambios a nivel social agudos, como el reforzamiento de conductas prosociales, y crónicos, como la disminución en las tareas empáticas y la aparición de conductas agresivas. En cuanto a las funciones mentales superiores, se encontró que en consumidores crónicos hay una disminución del procesamiento y almacenamiento de la información, alteraciones en la memoria operativa, verbal y visual, pobreza en el lenguaje verbal y dificultad en la toma de decisiones asociada a mayor impulsividad. En el afecto, se evidenció que las personas presentaban síntomas asociados con depresión y ansiedad, y aumento de la prevalencia de episodios psicóticos, tanto aguda como crónicamente. Según estos hallazgos, el MDMA es una sustancia con efectos nocivos en el procesamiento de tareas de cognición social, funciones ejecutivas, modulación afectiva, percepción de la realidad y, finalmente, deterioro de la calidad de vida del consumidor crónico.
Descargas
Referencias
Hoffman R. MDMA (ecstasy) intoxication. Uptodate. 2020. Disponible en: https://www.uptodate.com/contents/mdma-ecstasy-intoxication?search=mdma&source=search_result&selectedTitle=1~109&usage_type=default&display_rank=1#H9
White M. How MDMA’s pharmacology and pharmacokinetics drive desired effects and harms. 2014. American College of Clinical Pharmacology. 54(3):245-251. DOI: 10.1002/jcph.266
Lyttle T, Montagne M. Drugs, music and ideology: a social pharmacological interpretation of the acid house movement. Int J Addictions, 27 (10):1159-77. DOI: 10.3109/10826089209047341
Oesterheld J., et al. Ecstasy: Pharmacodynamic and Pharmacokinetic Interactions. Psychosomatics. 2004. 45(1):84-87. DOI: 10.1176/appi.psy.45.1.84
Loftis MJ, Janowsky A. Neuroimmune Basis of Methamphetamine Toxicity. International Review of Neurobiology. 2014; 118:165-197. DOI: 10.1016/B978-0-12-801284-0.00007-5
Robledo P. Las anfetaminas. Trastornos Adictivos. 2008; 10(3): 166-173. DOI: 10.1016/S1575-0973(08)76363-3
Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney L, Rawson R. Depression Among Methamphetamine Users. J Nerv Ment Dis. 2009; 197(4):225-231.
Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti ME. Differential effects of MDMA and methylphenidate on social cognition. Journal of Psychopharmacology. 2014; 28(9):847-856. DOI: 10.1177/0269881114542454
Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, Preller, KH, Quednow BB. MDMA enhances emotional empathy and prosocial behavior. Social cognitive and affective neuroscience. 2014; 11:1645-1652. DOI: 10.1093/scan/nst161
Morley KC, McGregor IS. (±)-3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) increases social interaction in rats. European Journal of Pharmacology. 2000; 408(1):41-49. DOI: 10.1016/s0014-2999(00)00749-4
Fone KC, Becket S. et al. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology. 2002; 159:437-444. DOI: 10.1007/s00213-001-0931-z
Ando RD, Benko A, Ferrington L, Kirilly E, Kelly PAT, Bagdy G. Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test. Neuropharmacology. 2006; 50(7):884-896. DOI: 10.1016/j.neuropharm.2005.12.010
McGregor I, Clemens K, Van der Plasse G, Li K, Hunt G, Chen F, Lawrence A. Increased Anxiety 3 Months after Brief Exposure to MDMA (‘Ecstasy’) in Rats: Association with Altered 5-HT Transporter and Receptor Density. Neuropsychopharmacology. 2003; 28:1472-1484.
Karimi S, Jahanshahi M, Golalipour MJ. The Effect of MDMA-Induced Anxiety on Neuronal Apoptosis in Adult Male Rats’ Hippocampus. Folia Biologica (Praha). 2014; 60:187-191.
Wunderli MD, Vonmoos M, Treichler L, Zeller C, Dziobek I, Kraemer T, Baumgartner M, Seifritz E, Quednow B. Social Cognition and Interaction in Chronic Users of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”), International Journal of Neuropsychopharmacology. 2018; 21(4) 333-344. DOI: 10.1093/ijnp/pyx098
Kirkpatrick M, Delton AW, Robertson TE, de Wit H. Prosocial effects of MDMA: A measure of generosity. Journal of Psychopharmacology. 2015; 29(6):661-668. DOI: 10.1177/0269881115573806
Verheyden SL, Hadfield J, Calin T. Sub-acute effects of MDMA (±3,4-methylenedioxymethamphetamine, “ecstasy”) on mood: evidence of gender differences. Psychopharmacology. 2002; 161: 23-31. DOI: 10.1007/s00213-001-0995-9
Curren H, Rees H, Hoare T, Hoshi R, Bond A. Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users. Psicofarmacología, 2004; 173:425-433.
Hawkey A., April B., Galizio M., Effects of MDMA on olfactory memory and reversal learning in rats. Neurobiology of learning and Memory. 2014; 114:209-216. DOI: 10.1016/j.nlm.2014.06.012
Ricaurte GA, McCann UD. Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, ‘ecstasy’) and its potential to damage brain serotonin neurons. Neurotox Res. 2001. 3(85). DOI: 10.1007/bf03033232
Nulsen C, Fox A, Hammond G. Differential Effects of Ecstasy on Short-Term and Working Memory: A Meta-Analysis. Neuropsychol. 2010; 20:21-32. DOI 10.1007/s11065-009-9124-z
Becker B, Wagner D, Koester P, Bender K. Kabbasch C, Daumann J. Memory-related hippocampal functioning in ecstasy and amphetamine users. Psycopharmacology. 2013; 225:923-934. DOI: 10.1007/s00213-012-2873-z
Hallander B, Schouw M, Groot P, Hiosman H, Caan M, Barkhof F, Reneman L. Preliminary evidence of hippocampal damage in chronic users of ecstasy. Neurol Neurosurg Psychiatry. 2012;83:83-85. Doi:10.1136/jnnp.2010.228387
Gardner H, Lawn N, Fatovich D, et al. Acute Hippocampal Sclerosis Following Ecstasy Ingestion. Neurology. 2009; 73:567-569. DOI 10.1212/WNL.0b013e3181b2a684
Meneses A, Perez-García G, Ponce-Lopez T, Castillo C. Serotonin transporter and memory. Neuropharmacology. 2011; 61:355-363. DOI: 10.1016/j.neuropharm.2011.01.018
Bhide N, Lipto J., Cunningham J., Yamamoto B., Gudelsky G., Repeated exporsure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain. Brain Res. 2009; 1286:32-41. DOI: 10.1016/j.brainres.2009.06.042
Reneman L, Booij J, Majoie C, Brink W, Heeten G. Investigation the potential neurotoxicity of Ecstasy (MDMA): an imaging approach. Human Psychopharmacology: Clinical and Experimental. 2001. 16 (8). DOI: 10.1002/hup.347
De Win MM, Jager G, Booij J, et al. Neurotoxic effects of ecstasy on the thalamus. Br J Psychiatry. 2008; 193(4):289-296. DOI: 10.1192/bjp.bp.106.035089.
McCann U, Wilson M, Sgambati F, et al., Sleep Deprivation Differentially Impairs Cognitive Performance in Abstinent Methylenedioxymethamphetamine (Ecstasy) Users. J Neurosci. 2009; 29(44):14050-15056. DOI: 10.1523/JNEUROSCI.4654-09.2009
Thomasius R, Zapletalova P, Petersen K, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacology. 2006; 20(2):211-225. DOI: 10.1177/0269881106059486
Kuypers K, Theunissen E, Van Wel J, de Sousa Fernandes E. Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective. Plos One. 2016; 11(2). DOI: 10.1371/journal.pone.0149438
Wagner D, Tkotz S, Koester P, Becker B, et al. Learning, Memory, and Executive Function in New MDMA Users: A 2- year Follow-Up Study. Frontiers in neuroscience. 2015; 9 (445). DOI: 10.3389/fnins.2015.00445
Volkow N. Years of Animal Research Proves MDMA (“Ecstasy”) Can Damage Neurons; MDMA’s Effects on the Human Brain Are Being Studied. National Institute on Drug Abuse. 2014. Disponible en: https://archives.drugabuse.gov/about-nida/directors-page/messages-director/2004/04/years-animal-research-proves-mdma-ecstasy-can-damage-neurons-mdmas-effects-human-brain-are-being
Alting von Geusau N, Stalenhoef P, Huizinga M. Snel J, Ridderinkhof KR. Impaired executive function in male MDMA (“ecstacy”) users. Psychopharmacology. 2004; 175(3):331-341. DOI: 10.1007/s00213-004-1832-8
Quednow BB, Kühn K, Hoppe C, et al. Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA (“Ecstasy”). Psychopharmacology. 2007; 189:517-530. DOI: 10.1007/s00213-005-0256-4
Morgan M, Impallomeni L, Pirona A, et al. Elevated Impulsivity and Impaired Decision-Making in Abstinent Ecstasy (MDMA) Users Compared to Polydrug and Drug-Naïve Controls. Neuropsychopharmacol. 2006. 31:1562-1573. DOI: 10.1038/sj.npp.1300953
Fox H, McLean A, Turner J, Parrott A, Rogers R., Sahakian B. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (“ecstasy”) polydrug users. Psychopharmacology. 2002; 162(2):203-214. DOI: 10.1007/s00213-002-1071-9
Fagundo AB, Cuyàs E, Verdejo-Garcia A, Khymenets O, Langohr K, Martín-Santos R, Farre M, De la Torre R. The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users. Journal of Psychopharmacology. 2010; 24(9):1381-1393. DOI: 10.1177/0269881109354926
Baggott MJ, Kirkpatrick MG, Bedi G, de Wit H. Visión íntima: MDMA cambia la forma en que las personas hablan de otras personas importantes. Revista de Psicofarmacología. 2015; 29(6): 669-677. DOI: 10.1177/0269881115581962
Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney L, Rawson R. Depression Among Methamphetamine Users. J Nerv Ment Dis. 2009; 197(4):225-231. DOI: 10.1097/NMD.0b013e31819db6fe
Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: Preliminary findings. Am J Addict. 2004; 13:248-255. DOI: 10.1080/10550490490459915
Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004; 61:807-816. DOI: 10.1001/archpsyc.61.8.807
Copeland AL, Sorensen JL. Differences between methamphetamine users and cocaine users in treatment. Drug Alcohol Depend. 2001; 62:91-95. DOI: 10.1016/s0376-8716(00)00164-2
Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, Iguchi M. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13:181-190. DOI: 10.1080/10550490490436055
Lisdahl K, Shear P. Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: Contributions of polydrug use. Drug and Alcohol Dependence. 2007; 87:303-311. DOI: 10.1016/j.drugalcdep.2006.09.003
Milani RM, Parrott AC, Turner JJD, and Fox H. Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users. Addict Behav. 2004; 29:965-971. DOI: 10.1016/j.addbeh.2004.02.044
Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict. 2000; 9: 28-37. DOI: 10.1080/10550490050172209
McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006; 101:1473-1478. DOI: 10.1111/j.1360-0443.2006.01496.x
Mahoney JJ, Kalechstein AD, De, La, Garza R, Newton TF. Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. Am J Addict. 2008; 17:83-98. DOI: 10.1080/10550490701861201
Iwanami A, Sugiyama A, Kuroki N, et al. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatr Scand. 1994; 89:428-432. DOI: 10.1111/j.1600-0447.1994.tb01541.x
Bousman CA, McKetin R, Burns R, Woods SP, Morgan EE, Atkinson JH, et al. Typologies of positive psychotic symptoms in methamphetamine dependence. Am J Addict. 2015; 24:94-7. DOI: 10.1111/ajad.12160.
Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Hsiao CC, et al. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med. 2003; 33:1407-14. DOI: 10.1017/s0033291703008353
Hong G, Yan Z, Haifeng J, Youwei Z, Tianzhen C, Haoye T, et al. A Research of Methamphetamine Induced Psychosis in 1,430 Individuals With Methamphetamine Use Disorder: Clinical Features and Possible Risk Factors. Front Psychiatry. 2018; 9:551. DOI: 10.3389/fpsyt.2018.00551
Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, et al. Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat. (2008) 35:445-50. DOI: 10.1016/j.jsat.2007.12.004
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2022 Salutem Scientia Spiritus
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La Revista Salutem Scientia Spiritus usa la licencia Creative Commons de Atribución – No comercial – Sin derivar: Los textos de la revista son posibles de ser descargados en versión PDF siempre que sea reconocida la autoría y el texto no tenga modificaciones de ningún tipo.
